AR084315A1 - Anticuerpos anti-notch1 - Google Patents

Anticuerpos anti-notch1

Info

Publication number
AR084315A1
AR084315A1 ARP110104711A AR084315A1 AR 084315 A1 AR084315 A1 AR 084315A1 AR P110104711 A ARP110104711 A AR P110104711A AR 084315 A1 AR084315 A1 AR 084315A1
Authority
AR
Argentina
Prior art keywords
antibodies
region
notch1
pharmaceutical compositions
notch1 antibodies
Prior art date
Application number
Other languages
English (en)
Inventor
Lioudmila Gennadievna Tchistiakova
Kenneth G Geles
Bin Zhou
Stephen-Gao Yijie Bing
Joel Bard
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of AR084315A1 publication Critical patent/AR084315A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Anticuerpos que se ligan a Notch1. También provee métodos para preparar los anticuerpos, composiciones farmacéuticas que comprenden estos anticuerpos y métodos para el tratamiento de trastornos con los anticuerpos y las composiciones farmacéuticas.Reivindicación 1: Un anticuerpo que se liga a Notch1, caracterizado porque comprende: una región variable de la cadena pesada que tiene una región CDR1, una región CDR2 y una región CDR3 de la región variable de la cadena pesada que comprende SEQ ID Nº 71.
ARP110104711 2010-12-15 2011-12-15 Anticuerpos anti-notch1 AR084315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42357810P 2010-12-15 2010-12-15
US201161552578P 2011-10-28 2011-10-28

Publications (1)

Publication Number Publication Date
AR084315A1 true AR084315A1 (es) 2013-05-08

Family

ID=45444674

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP110104711 AR084315A1 (es) 2010-12-15 2011-12-15 Anticuerpos anti-notch1

Country Status (20)

Country Link
US (2) US9127060B2 (es)
EP (1) EP2651977A2 (es)
JP (1) JP6016800B2 (es)
KR (2) KR20150088334A (es)
CN (2) CN105884896A (es)
AR (1) AR084315A1 (es)
AU (2) AU2011342799B2 (es)
BR (1) BR112013015122A2 (es)
CA (1) CA2821130C (es)
CO (1) CO6791565A2 (es)
HK (1) HK1194388A1 (es)
MX (1) MX346995B (es)
NZ (1) NZ611785A (es)
PE (1) PE20141109A1 (es)
PH (1) PH12017500864A1 (es)
RU (1) RU2622083C2 (es)
SA (1) SA111330060B1 (es)
SG (1) SG191039A1 (es)
TW (1) TWI471333B (es)
WO (1) WO2012080926A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
EP2064325B1 (en) 2006-09-01 2011-12-07 Therapeutic Human Polyclonals, Inc. Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
PE20090321A1 (es) 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
CA2765989C (en) 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
NZ611785A (en) 2010-12-15 2015-04-24 Wyeth Llc Anti-notch1 antibodies
US20150232570A1 (en) * 2012-09-21 2015-08-20 Oncomed Pharmaceuticals, Inc. Methods of Treating Hematological Malignancies with Notch1 Antibodies
TW201431880A (zh) 2012-11-07 2014-08-16 Pfizer 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體
CA2952315A1 (en) 2014-07-11 2016-01-14 Genentech, Inc. Notch pathway inhibition
WO2016069906A1 (en) 2014-10-29 2016-05-06 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
CN113862300A (zh) * 2015-10-29 2021-12-31 豪夫迈·罗氏有限公司 具有共同轻链的转基因兔
CN105585636B (zh) * 2015-11-24 2020-03-03 南方医科大学 一种人NOTCH1 NICD蛋白Ser2162位点磷酸化抗体及其制备方法和应用
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
WO2019199165A1 (en) * 2018-04-10 2019-10-17 Stichting Sanquin Bloedvoorziening Chimeric notch receptors
KR102499678B1 (ko) * 2020-02-27 2023-02-15 주식회사 베르티스 암의 진단용 조성물

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4754065A (en) 1984-12-18 1988-06-28 Cetus Corporation Precursor to nucleic acid probe
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4800159A (en) 1986-02-07 1989-01-24 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5278299A (en) 1991-03-18 1994-01-11 Scripps Clinic And Research Foundation Method and composition for synthesizing sialylated glycosyl compounds
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
AU669124B2 (en) 1991-09-18 1996-05-30 Kyowa Hakko Kirin Co., Ltd. Process for producing humanized chimera antibody
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
WO1993010260A1 (en) 1991-11-21 1993-05-27 The Board Of Trustees Of The Leland Stanford Junior University Controlling degradation of glycoprotein oligosaccharides by extracellular glycosisases
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
PT1071700E (pt) 1998-04-20 2010-04-23 Glycart Biotechnology Ag Modificação por glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
EP1117778A2 (en) 1998-10-02 2001-07-25 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Methods and compositions for inducing differentiation and apoptosis in cells that overexpress the notch protein
US20030035798A1 (en) 2000-08-16 2003-02-20 Fang Fang Humanized antibodies
ES2694002T3 (es) 1999-01-15 2018-12-17 Genentech, Inc. Polipéptido que comprende una región Fc de IgG1 humana variante
PT1914244E (pt) 1999-04-09 2013-07-26 Kyowa Hakko Kirin Co Ltd Processo para regular a actividade de moléculas funcionais sob o ponto de vista imunológico
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
CN1331214A (zh) * 2000-06-30 2002-01-16 上海博德基因开发有限公司 一种新的多肽——人缺刻蛋白24.64和编码这种多肽的多核苷酸
WO2002059285A1 (en) 2000-10-27 2002-08-01 Fred Hutchinson Cancer Research Center Methods for immortalizing cells
CN1376686A (zh) * 2001-03-22 2002-10-30 上海博德基因开发有限公司 一种多肽——缺刻蛋白－34.32和编码这种多肽的多核苷酸
EP1443961B1 (en) 2001-10-25 2009-05-06 Genentech, Inc. Glycoprotein compositions
US20030148954A1 (en) 2001-11-02 2003-08-07 Wisconsin Alumni Research Foundation Agents and methods for modulating activator protein-1-mediated cellular processes
JP2005526701A (ja) 2001-11-14 2005-09-08 ロランティス リミテッド 内科療法
JPWO2003085107A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 ゲノムが改変された細胞
JP4558485B2 (ja) 2002-07-18 2010-10-06 正康 大河内 Ｎｏｔｃｈ由来新規ポリペプチドおよびそれを用いたバイオマーカー並びに試薬
NZ540730A (en) 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
BRPI0416934A (pt) 2003-11-26 2007-01-16 Health Research Inc método para reduzir a gravidade dos distúrbios das células plasmáticas ou para o tratamento dos distúrbios das células plamáticas, método para reduzir a dose de um agente citotóxico, e, método para reduzir a produção de il-6 ou de vegf pelos fibroblastos que se acham em contato com as células plasmáticas cancerosas
WO2006001956A2 (en) 2004-05-20 2006-01-05 The Board Of Trustees Of The University Of Illinois Compositions for inhibiting cell growth and inducing apoptosis in cancer cells and methods of use thereof
US20070077245A1 (en) 2004-08-04 2007-04-05 The Brigham And Women's Hospital, Inc. NOTCH mutations leading to increased receptor signaling
WO2006053063A2 (en) 2004-11-05 2006-05-18 The Regents Of The University Of California Notch-1 assay to detect neurodegenerative diseases
AU2005302846A1 (en) * 2004-11-10 2006-05-18 Hubrecht Laboratorium Treatment of an intestinal adenoma and/or adenocarcinoma by inhibition of notch pathway activation
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
WO2006092062A1 (en) 2005-03-04 2006-09-08 The Hospital For Sick Children Methods for cancer prognosis
US20070072222A1 (en) 2005-09-23 2007-03-29 Franziska Boess FABP4 as biomarker for toxic effect
US20090305310A1 (en) 2005-11-22 2009-12-10 University Of Vermont And State Agricultural College Methods for Determining Notch Signaling and Uses Thereof
WO2008057144A2 (en) 2006-05-15 2008-05-15 The Brigham And Women's Hospital, Inc. Functional negative regulatory domain sequences from human notch1 and 2 and isolated lnr domains from human notch1
PL2032166T3 (pl) 2006-06-13 2013-09-30 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworów
UA98632C2 (ru) * 2006-12-18 2012-06-11 Дженентек, Інк. Антагонистические антитела к notch3 и их применение для профилактики и лечения связанных с notch3 заболеваний
JP2010520280A (ja) 2007-03-05 2010-06-10 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム ＮｏｔｃｈまたはＮｕｍｂ特異的免疫療法との相乗効果を有する、癌細胞の再生のネガティブな遺伝的制御
PE20090321A1 (es) * 2007-06-04 2009-04-20 Genentech Inc Anticuerpos anti-notch1 nrr, metodo de preparacion y composicion farmaceutica
US8119366B2 (en) 2007-10-05 2012-02-21 Trojan Technologies, Ltd. Antennapedia-dominant negative mastermind-like construct
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
US20110286916A1 (en) * 2008-11-20 2011-11-24 Jose Miguel Aste-Amezaga Generation and characterization of anti-notch antibodies for therapeutic and diagnostic use
CA2765989C (en) 2009-06-18 2016-11-29 Pfizer Inc. Anti notch-1 antibodies
WO2011041336A2 (en) 2009-09-30 2011-04-07 Genentech, Inc. Methods of treating cancer using notch antagonists
WO2011088215A2 (en) 2010-01-13 2011-07-21 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
NZ611785A (en) 2010-12-15 2015-04-24 Wyeth Llc Anti-notch1 antibodies
WO2012080891A1 (en) 2010-12-15 2012-06-21 Rinat Neuroscience Corp. Anti-notch-1 antibodies

Also Published As

Publication number Publication date
AU2016219704A1 (en) 2016-09-15
TWI471333B (zh) 2015-02-01
KR101580726B1 (ko) 2015-12-29
CN103547594B (zh) 2016-05-11
US20160002331A1 (en) 2016-01-07
KR20130108430A (ko) 2013-10-02
CN103547594A (zh) 2014-01-29
HK1194388A1 (zh) 2014-10-17
CA2821130C (en) 2017-11-07
PH12017500864A1 (en) 2017-12-11
AU2011342799B2 (en) 2016-06-09
MX346995B (es) 2017-04-06
RU2622083C2 (ru) 2017-06-09
PE20141109A1 (es) 2014-09-24
RU2013126494A (ru) 2015-01-20
AU2011342799A1 (en) 2013-07-04
NZ611785A (en) 2015-04-24
CO6791565A2 (es) 2013-11-14
US9127060B2 (en) 2015-09-08
TW201302787A (zh) 2013-01-16
WO2012080926A3 (en) 2012-10-04
KR20150088334A (ko) 2015-07-31
MX2013006875A (es) 2013-07-05
SG191039A1 (en) 2013-08-30
CA2821130A1 (en) 2012-06-21
WO2012080926A2 (en) 2012-06-21
EP2651977A2 (en) 2013-10-23
CN105884896A (zh) 2016-08-24
JP2014503205A (ja) 2014-02-13
SA111330060B1 (ar) 2015-06-04
BR112013015122A2 (pt) 2017-05-30
US20130266594A1 (en) 2013-10-10
JP6016800B2 (ja) 2016-10-26

Similar Documents

Publication Publication Date Title
AR084315A1 (es) Anticuerpos anti-notch1
ES2543174T3 (es) Composición medicinal para el tratamiento y/o la prevención del cáncer
PE20150002A1 (es) Anticuerpos anti-fcrn
PE20131209A1 (es) Anticuerpos anti-fap
PE20140247A1 (es) Anticuerpos anti-cd38
AU2018256487A1 (en) Antibodies that bind to TL1A and their uses
ES2670621T3 (es) Anticuerpos que se unen a OX40 y sus usos
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
CO6410312A2 (es) Moléculas de anticuerpo que tienen especificidad por humano ox40
AR102554A1 (es) Receptores quiméricos de antígeno anti-cldn y métodos de uso
EA201500995A1 (ru) Биспецифические антитела, специфические в отношении fap и dr5, антитела, специфические в отношении dr5, и способы их применения
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
PE20130159A1 (es) Anticuerpos anti-cd40
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
NZ712765A (en) Antibodies that bind csf1r
EA201491214A1 (ru) Композиции и способы применения антител, нацеленных на фактор p
AR105267A1 (es) Anticuerpos de unión a tau
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20171060A1 (es) Receptores quimericos de antigeno anti-cldn y metodos de uso
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CO2017004753A2 (es) Anticuerpos que se unen a ccr6
EA201400447A1 (ru) АНТИТЕЛА К CD1d

Legal Events

Date Code Title Description
FB Suspension of granting procedure